See the rest here:
AnHeart and Innovent Releases Preliminary Results from the Phase II TRUST Trial of Taletrectinib in ROS1 Fusion Positive NSCLC at the ASCO 2021 Annual...

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh